144 related articles for article (PubMed ID: 38010641)
1. [Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy].
Sotnikova TN; Polushkina TV; Danilova NV
Arkh Patol; 2023; 85(6):70-75. PubMed ID: 38010641
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Expression of Programmed Cell Death Ligand 1 (PD-L1) in Human Cutaneous Malignant Melanoma: A Narrative Review with Historical Perspectives.
Cazzato G; Lettini T; Colagrande A; Trilli I; Ambrogio F; Laface C; Parente P; Maiorano E; Ingravallo G
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372432
[TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial Relationship.
Fiorentino V; Pizzimenti C; Franchina M; Pepe L; Russotto F; Tralongo P; Micali MG; Militi GB; Lentini M
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203846
[TBL] [Abstract][Full Text] [Related]
5. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.
Kowalski A; Malinowska K; Olszewski J; Zielińska-Bliźniewska H
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356594
[TBL] [Abstract][Full Text] [Related]
6. CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
Kong T; Ahn R; Yang K; Zhu X; Fu Z; Morin G; Bramley R; Cliffe NC; Xue Y; Kuasne H; Li Q; Jung S; Gonzalez AV; Camilleri-Broet S; Guiot MC; Park M; Ursini-Siegel J; Huang S
Cancer Res; 2020 Feb; 80(3):444-457. PubMed ID: 31722999
[TBL] [Abstract][Full Text] [Related]
7. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
8. PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.
Stevenson VB; Perry SN; Todd M; Huckle WR; LeRoith T
Vet Pathol; 2021 Jul; 58(4):692-698. PubMed ID: 34169800
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,
Morales-Betanzos CA; Lee H; Gonzalez Ericsson PI; Balko JM; Johnson DB; Zimmerman LJ; Liebler DC
Mol Cell Proteomics; 2017 Oct; 16(10):1705-1717. PubMed ID: 28546465
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Kim JM; Chen DS
Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
14. [Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors].
Huang HF; Zhu H; Yang XT; Guo XY; Li SS; Xie Q; Tian XB; Yang Z
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):410-414. PubMed ID: 31216825
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
[TBL] [Abstract][Full Text] [Related]
20. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK; Molero M; Martinez Morilla S; Baena J; Vathiotis IA; Gavrielatou N; Castro-Labrador L; de Garibay GR; Adradas V; Orive D; Valencia K; Calvo A; Montuenga LM; Ponce Aix S; Schalper KA; Herbst RS; Paz-Ares L; Rimm DL; Zugazagoitia J
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
